[Future geriatric care demands expanded capacity of small institutional units].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to O Lundvall.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Carbamazepine or placebo were given in random order, during two four-week periods, in a double-blind, cross-over trial in six patients presenting with symptoms of restless legs. On global evaluation after completing the trial three patients and the physician preferred to continue treatment with carbamazepine. In the remaining three cases both the physician and the patients preferred not to continue with either of the treatments. However, the patients who did not give any preference also had less pronounced symptoms during treatment with carbamazepine. No patient felt better during treatment with placebo as compared to carbamazepine. The results indicate that certain patients have fewer attacks of restless legs during treatment with carbamazepine.
The effect of phlebotomy on 44 patients (33 men and 11 women) with porphyria cutanea tarda (PCT) is described. All had typical biochemical and clinical signs of PCT. The patients were bled until slight anemia and signs of iron deficiency. In patients who were bled frequently and who were not given iron supplements in conjunction with phlebotomy, urinary uroporphyrin excretion decreased to 1 mg (or 1.2 mumol) a day or less in 1-8 months (mean 4 months) and then continued to decrease long after the treatment had been stopped and became normal in many patients. A decrease in porphyrin excretion comparable to that in patients treated with phlebotomy occurred in only two out of 12 controls. Remission occurred in patients treated with phlebotomy who had iron overload as well as in patients with quantitatively normal iron stores and in patients abstaining from alcohol as well as in patients who continued their abuse of alcohol. The disappearance of skin fragility and ulcers coincided roughly with the time when the urinary excretion of uroporphyrin decreased to about 1 mg (1.2 mumol) a day. After 43 remissions (in 43 patients) not followed by iron medication, one relapse occurred after a period of 20 months. In 5 patients in whom their iron stores were replenished a relapse occurred in all within 18 months. After longer observation periods relapses occurred also after remissions not followed by iron medication. During observation periods of 3-10 years 15 out of 41 patients relapsed biochemically. These had re-accumulated iron stores spontaneously. The results indicate that phlebotomy is consistently effective and probably exerts its effect mainly by reduction of iron stores.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Fine needle aspiration biopsy smears from 19 patients with porphyria cutanea tarda were studied by fluorescence microscopy. Fluorescence was arbitrarily graded from 0 to 4. All patients-those with clinically manifest as well as those with latent disease-showed bright red fluorescence of porphyrin type in the liver cells, though in latent cases the fluorescence commonly was of a low grade. In patients with manifest disease fluorescence of grade 3 or 4 was present. In patients with fluorescence of grades 1 or 2 the uroporphyrin excretion in urine was normal or slightly increased. At higher grades all levels of porphyrin excretion were encountered. Of 22 control subjects, only one showed hepatic fluorescence of a porphyrin character. The control patient with a positive finding was found to have definitely increased urinary uroporphyrin excretion and probably has latent porphyria cutanea tarda. The procedure described should be useful as a screening test for hepatic cutaneous porphyria.
Explore the source record for details and available documents.